Trial · NCT00924352
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Determination of the Maximum Tolerated Dose (MTD) of Dasatinib When Given in Combination With Ixabepilone (Phase I) | Ixabepilone + Dasatinib | 100 | mg daily | ||
| Determination of the Maximum Tolerated Dose (MTD) of Ixabepilone When Given in Combination With Dasatinib (Phase I) | Ixabepilone + Dasatinib | 20 | mg/m2 | ||
| Determination of the Dose Limiting Toxicities (DLTs) of the Combination of Dasatinib and Ixabepilone (Phase I) | Ixabepilone + Dasatinib (Dose Level 0) | DLT: Grade 4 Thrombocytopenia | 0 | participants | |
| Determination of the Dose Limiting Toxicities (DLTs) of the Combination of Dasatinib and Ixabepilone (Phase I) | Ixabepilone + Dasatinib (Dose Level 1) | DLT: Grade 4 Thrombocytopenia | 0 | participants | |
| Determination of the Dose Limiting Toxicities (DLTs) of the Combination of Dasatinib and Ixabepilone (Phase I) | Ixabepilone + Dasatinib (Dose Level 2) | DLT: Grade 4 Thrombocytopenia | 1 | participants | |
| Determination of the Dose Limiting Toxicities (DLTs) of the Combination of Dasatinib and Ixabepilone (Phase I) | Ixabepilone + Dasatinib (Dose Level 0) | DLT: Grade 4 Leukopenia | 0 | participants | |
| Determination of the Dose Limiting Toxicities (DLTs) of the Combination of Dasatinib and Ixabepilone (Phase I) | Ixabepilone + Dasatinib (Dose Level 1) | DLT: Grade 4 Leukopenia | 0 | participants | |
| Determination of the Dose Limiting Toxicities (DLTs) of the Combination of Dasatinib and Ixabepilone (Phase I) | Ixabepilone + Dasatinib (Dose Level 2) | DLT: Grade 4 Leukopenia | 1 | participants | |
| Best Overall Response of the Combination of Dasatinib and Ixabepilone (Phase II) | Ixabepilone + Dasatinib | Complete Response | 0 | participants | |
| Best Overall Response of the Combination of Dasatinib and Ixabepilone (Phase II) | Ixabepilone + Dasatinib | Partial Response | 4 | participants | |
| Best Overall Response of the Combination of Dasatinib and Ixabepilone (Phase II) | Ixabepilone + Dasatinib | Stable Disease | 11 | participants | |
| Best Overall Response of the Combination of Dasatinib and Ixabepilone (Phase II) | Ixabepilone + Dasatinib | Progressive Disease | 23 | participants | |
| Best Overall Response of the Combination of Dasatinib and Ixabepilone (Phase II) | Ixabepilone + Dasatinib | Not Evaluable | 12 | participants | |
| Clinical Benefit Rate of the Combination of Dasatinib and Ixabepilone (Phase II) | Ixabepilone + Dasatinib | 26.0 | percentage of participants | ||
| Incidence of Grade 3 Adverse Events (AEs) With the Combination of Dasatinib and Ixabepilone (Phase II) | Ixabepilone + Dasatinib | 31 | participants | ||
| Incidence of Grade 4 Adverse Events (AEs) With the Combination of Dasatinib and Ixabepilone (Phase II) | Ixabepilone + Dasatinib | 5 | participants | ||
| Evaluation of Progression-free Survival (PFS) of the Combination of Dasatinib and Ixabepilone (Phase II) | Ixabepilone + Dasatinib | 6.01 | 95% Confidence Interval 2.92 to 8.08 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00924352/results